CAMBRIDGE, Mass.--(BUSINESS WIRE)--Idera Pharmaceuticals, Inc. (AMEX: IDP), today announced interim results from a Phase 1 clinical trial being conducted by the Company evaluating IMO-2055, the Company’s lead Toll-Like Receptor (TLR) 9 agonist, in combination with gemcitabine and carboplatin in patients with advanced solid tumors. The data were presented in a poster entitled “Initial phase 1 results of gemcitabine, carboplatin and IMO-2055, a toll-like receptor agonist, in patients with advanced solid tumors,” by Shakun Malik, M.D., Chief of the Center for Thoracic Medical Oncology at the Lombardi Comprehensive Cancer Center at Georgetown University Medical Center, and principal investigator for the trial, during the 12th World Conference on Lung Cancer taking place in Seoul, Korea, September 2-6, 2007.
